

European Heart Journal

Volume 42 No. 48 December 2021

ISSUE @ A GLANCE



Sodium-glucose co-transporter inhibitors, iron therapy, and checkpoint inhibitors: new clinical and translational pieces of the heart failure puzzle

F. Crea

4871

CardioPulse

How an 'accidental doctor' became a renowned cardiologist

M. Nicholls

4876

Making connections to overcome arrhythmias

M. Nicholls

4878

Leveraging non-coding RNAs to fight cardiovascular disease: the EU-CardioRNA network

E.L. Robinson, C. Emanuelli, F. Martelli, and Y. Devaux

4881

Appointment as Board Reviewer: Ik-Kyung Jang, MD, PhD

4884

Weekly Journal Scan

Quadruple combination of quarter doses of blood pressure-lowering agents: a string QUARTET in the symphony of hypertension management?

M. Volpe and C. Patrono

4885

VIEWPOINT

Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations

J. Butler, S.D. Anker, G. Filippatos, M.S. Usman, J.P. Ferreira, F. Zannad, and M. Packer

4887

FAST TRACK CLINICAL RESEARCH

Heart Failure and Cardiomyopathies

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial*

B.L. Neuen, M. Oshima, V. Perkovic, R. Agarwal, C. Arnott, G. Bakris, C.P. Cannon, D.M. Charytan, R. Edwards, J.L. Górriz, M.J. Jardine, A. Levin, B. Neal, L. De Nicola, C. Pollock, N. Rosenthal, D.C. Wheeler, K.W. Mahaffey, and H.J.L. Heerspink

4891

Editorial

SGLT2 inhibitors: the story continues to unfold

I.L. Piña

4902

Heart Failure and Cardiomyopathies

The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial

P. Martens, M. Dupont, J. Dauw, P. Nijst, L. Herbots, P. Dendale, P. Vandervoort, L. Bruckers, W.H.W. Tang, and W. Mullens

4905

Editorial

Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure?

E.A. Jankowska and P. Ponikowski

4915

Heart Failure and Cardiomyopathies

Prognostic value of comprehensive intracoronary physiology assessment early after heart transplantation

J.-M. Ahn, F.M. Zimmermann, S. Arora, O.-G. Solberg, O. Angerås, K. Rolid, M. Rafique, L. Aaberge, K. Karason, K. Okada, H. Luikart, K.K. Khush, Y. Honda, N.H.J. Pijls, S.E. Lee, J.-J. Kim, S.-J. Park, L. Gullestad, and W.F. Fearon

4918

Editorial

Early diagnosis of cardiac allograft vasculopathy: biopsy, liquid biopsy, non-invasive imaging, coronary imaging, or coronary physiology?

F. Alfonso, F. Rivero, and J. Segovia-Cubero

4930

CLINICAL RESEARCH

Heart Failure and Cardiomyopathies

The Stanford experience of heart transplantation over five decades

Y. Zhu, B. Lingala, M. Baiocchi, V. Toro Arana, K.M. Williams, Y. Shudo, P.E. Oyer, and Y.J. Woo

4934

Editorial

Improving survival after heart transplantation despite increasing complexity

D. Mancini, G.T. Gibson, and S. Rangasamy

4944

TRANSLATIONAL RESEARCH

Heart Failure and Cardiomyopathies

Effects of canagliflozin on human myocardial redox signalling: clinical implications

H. Kondo, I. Akoumianakis, I. Badi, N. Akawi, C.P. Kotanidis, M. Polkinghorne, I. Stadiotti, E. Sommariva, A.S. Antonopoulos, M.C. Carena, E.K. Oikonomou, E.M. Reus, R. Sayeed, G. Krasopoulos, V. Srivastava, S. Farid, S. Chuaiphichai, C. Shirodaria, K.M. Channon, B. Casadei, and C. Antoniades

4947

Editorial

Canagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage

G.G. Schiattarella and D. Bode

4961

META ANALYSIS

Heart Failure and Cardiomyopathies

Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis

C. Dolladille, J. Akroun, P.-M. Morice, A. Domp Martin, E. Ezine, M. Sassier, A. Da-Silva, A.-F. Plane, D. Legallois, J.-M. L'Orphelin, and J. Alexandre

4964

Editorial

Immune checkpoint inhibitors and cardiovascular events among patients with cancer: a window into the critical role of the immune system in cardiovascular biology

L. Kondapalli and T.G. Neilan

4978

DISCUSSION FORUM

Percutaneous intervention in patients with cancer: can we offer an improvement in safety?

I. Lozano, J.M. Vegas, and J. Rondan

4981

Decision making in percutaneous coronary intervention in patients with cancer: balancing ischaemic and bleeding risk

M.A. Mamas

4982

CARDIOVASCULAR FLASHLIGHT

Para-aortic channel in congenital heart disease: computed tomography and transoesophageal echography depiction of an undescribed type of interatrial communication

B. Mehier, A.-S. Da Silva, and J.-N. Dacher

4904

Spontaneous intramyocardial haemorrhage in a patient with wild-type transthyretin cardiac amyloidosis

C. Liu, W.R.T. Witschey, P. Santangeli, and Y. Han

4929